Japanese drugmaker Takeda announced its cancer medication Ninlaro will be subject to its 340B contract pharmacy policy.

Takeda Becomes 29th Drugmaker to Implement 340B Contract Pharmacy Restrictions

December 18, 2023 William Newton, Associate Editor/Senior Writer Views

Japanese pharmaceutical giant Takeda last Friday became the 29th drugmaker to place conditions on 340B pricing in the contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!